Drug Eruption and Interactions - PHARMACEUTICAL REVIEW

526 TENIPOSIDE
TENIPOSIDE
Synonyms: VM-26; PTG; EPT
Trade name: Vumon (Bristol-Myers Squibb)
Indications: Acute lymphocytic leukemia, Non-Hodgkin’s
lymphoma, Small cell lung cancer
Category: Antineoplastic; Topoisomerase 2 inhibitor
Half-life: 45 minutes
Clinically important, potentially hazardous interactions
with: phenobarbital, phenytoin
Reactions
Skin
Facial edema
(1988): Nolte H+, Am J Pediatr Hematol Oncol 10(4), 308
Rash (sic)
(1986): de Vries EG+, Cancer Treat Rep 70(5), 595
Urticaria
(1988): Nolte H+, Am J Pediatr Hematol Oncol 10(4), 308
Mucosal
Mucositis
(1991): Schwartsmann G+, Eur J Cancer 27(12), 1637
Stomatitis (3%)
Hair
Hair – alopecia (31%)
(1992): Smit EF+, Semin Oncol 19(2 Suppl 6), 35
(1992): Smit EF+, Semin Oncol 19(2 Suppl 6), 40
(1992): Tummarello D+, Eur J Cancer 28A(6–7), 1081
(1991): Schwartsmann G+, Eur J Cancer 27(12), 1637
(1990): Pfeiffer P+, Gynecol Oncol 37(2), 230 (75%)
(1986): Bork E+, J Clin Oncol 4(4), 524
Eyes
Ocular hemorrhage
(1982): Razon-Veronesi S, Tumori 68(3), 253
Other
Allergic reactions (5–15%)
(1992): Wysocki M+, Wiad Lek 45(3–4), 91
(1985): Hayes FA+, Cancer Treat Rep 69(4), 439
Anaphylactoid reactions/Anaphylaxis
(1989): Siddall SJ+, Lancet 1(8634), 394
(1984): Koster B+, Klin Padiatr 196(3), 178 (2 cases)
Death
(1995): Postmus PE+, J Clin Oncol 13(3), 660
(1992): Smit EF+, Semin Oncol 19(2 Suppl 6), 35
(1988): Cerny T+, Eur J Cancer Clin Oncol 24(11), 1791
Hepatotoxicity (2%)
Hypersensitivity (2–11%)
(1991): Kellie SJ+, Cancer 67(4), 1070
(1989): Carstensen H+, Lancet 2(8653), 55
(1988): Nolte H+, Am J Pediatr Hematol Oncol 10(4), 308
(1986): O’Dwyer PJ+, J Clin Oncol 4(8), 1262
Injection-site phlebitis
Nephrotoxicity (2%)
(1981): Habibi B+, Lancet 1(8235), 1423
TENOFOVIR
Synonyms: PMPA; TDF
Trade name: Viread (Gilead)
Indications: Management of HIV Infections in combination with
at least two other antiretroviral agents
Category: Antiretroviral; Nucleotide analog reverse
transcriptase inhibitor
Half-life: 12.0–14.4 hours
Clinically important, potentially hazardous interactions
with: acyclovir, cidofovir, didanosine, valganciclovir
Reactions
Skin
Lichenoid eruption
(2004): Woolley IJ+, AIDS 18(13), 1857
Purpura
Rash (sic)
Other
Abdominal pain
(2002): Fung HB+, Clin Ther 24(10), 1515
Chills
Hypersensitivity
(2007): Lockhart SM+, AIDS 21(10), 1370
Nephrotoxicity
(2007): Gitman MD+, Expert Opin Drug Saf 6(2), 155
(2007): Gupta Samir K, AIDS Read 17(2), 102
(2007): Sax PE+, AIDS Read 17(2), 90, 99
(2006): Cirino CM+, AIDS 20(12), 1671
(2006): de la Prada F+, Nefrologia 26(5), 626
(2006): Gatanaga H+, AIDS Res Hum Retroviruses 22(8), 744
(2006): Izzedine H+, JInfectDis194(11), 1481
(2006): Lanzafame M+, Clin Infect Dis 42(11), 1656
(2006): Mathew G+, JGenInternMed21(11), C3
(2006): Scott JD+, HIV Clin Trials 7(2), 55
(2006): Valle R+, Adv Chronic Kidney Dis 13(3), 314
(2005): Antoniou T+, HIV Med 6(4), 284 (4%)
(2005): Fine DM, AIDS Read 15(7), 362
(2005): Izzedine H+, Am J Kidney Dis 45(5), 804
(2005): Padilla S+, AIDS Patient Care STDS 19(7), 421 (%)
(2004): Barrios A+, AIDS 18(6), 960
(2004): Hansen AB+, Scand J Infect Dis 36(5), 389
(2004): James CW+, Pharmacotherapy 24(3), 415
(2004): Rifkin BS+, Am J Med 117(4), 282
(2003): Perazella MA, Am J Med Sci 325(6), 349
(2002): Coca S+, Am J Med Sci 324(6), 342
(2002): Verhelst D+, Am J Kidney Dis 40(6), 1331
Neurotoxicity (3%)
(2004): Prescrire Int 13(73), 180 (3%)
Pain (fingers or toes)
Rhabdomyolysis
(2003): Callens S+, JInfect47(3), 262
TERAZOSIN
Trade names: Heitrin; Hitrin; Hytrin (Abbott); Hytrine;
Hytrinex; Itrin; Vicard
Indications: Hypertension, benign prostatic hypertrophy
Category: Adrenergic alpha-receptor antagonist
Half-life: 12 hours
Clinically important, potentially hazardous interactions
with: vardenafil